<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Care</journal-id><journal-id journal-id-type="hwp">diacare</journal-id><journal-id journal-id-type="pmc">dcare</journal-id><journal-id journal-id-type="publisher-id">Diabetes Care</journal-id><journal-title-group><journal-title>Diabetes Care</journal-title></journal-title-group><issn pub-type="ppub">0149-5992</issn><issn pub-type="epub">1935-5548</issn><publisher><publisher-name>American Diabetes Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27352955</article-id><article-id pub-id-type="pmc">5079608</article-id><article-id pub-id-type="publisher-id">2296</article-id><article-id pub-id-type="doi">10.2337/dc15-2296</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Care/Education/Nutrition/Psychosocial Research</subject></subj-group></article-categories><title-group><article-title>Correlates of Medication Adherence in the TODAY Cohort of Youth With Type 2 Diabetes</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Katz</surname><given-names>Lorraine Levitt</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Anderson</surname><given-names>Barbara J.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>McKay</surname><given-names>Siripoom V.</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Izquierdo</surname><given-names>Roberto</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Casey</surname><given-names>Terri L.</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Higgins</surname><given-names>Laurie A.</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wauters</surname><given-names>Aimee</given-names></name><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Hirst</surname><given-names>Kathryn</given-names></name><xref ref-type="aff" rid="aff8"><sup>8</sup></xref><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Nadeau</surname><given-names>Kristen J.</given-names></name><xref ref-type="aff" rid="aff9"><sup>9</sup></xref></contrib><on-behalf-of>for the TODAY Study Group</on-behalf-of><xref ref-type="fn" rid="fn3">*</xref><aff id="aff1"><sup>1</sup>Division of Endocrinology and Diabetes, Children's Hospital of Philadelphia, and Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA</aff><aff id="aff2"><sup>2</sup>Baylor College of Medicine, Houston, TX</aff><aff id="aff3"><sup>3</sup>Texas Children’s Hospital, Houston, TX</aff><aff id="aff4"><sup>4</sup>State University of New York Upstate Medical University, Syracuse, NY</aff><aff id="aff5"><sup>5</sup>University Hospitals Case Medical Center, Cleveland, OH</aff><aff id="aff6"><sup>6</sup>Pediatric, Adolescent and Young Adult Section, Joslin Diabetes Center, Boston, MA</aff><aff id="aff7"><sup>7</sup>University of Texas Health Science Center, San Antonio, TX</aff><aff id="aff8"><sup>8</sup>George Washington University Biostatistics Center, Rockville, MD</aff><aff id="aff9"><sup>9</sup>University of Colorado Anschutz Medical Campus, Aurora, CO</aff></contrib-group><author-notes><corresp id="cor1">Corresponding author: Kathryn Hirst, <email>khirst@bsc.gwu.edu</email>.</corresp></author-notes><pub-date pub-type="ppub"><month>11</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>28</day><month>6</month><year>2016</year></pub-date><volume>39</volume><issue>11</issue><fpage>1956</fpage><lpage>1962</lpage><history><date date-type="received"><day>21</day><month>10</month><year>2015</year></date><date date-type="accepted"><day>1</day><month>5</month><year>2016</year></date></history><permissions><copyright-statement>© 2016 by the American Diabetes Association.</copyright-statement><copyright-year>2016</copyright-year><license><ali:license_ref specific-use="vor" start_date="2016-10-20">http://www.diabetesjournals.org/content/license</ali:license_ref><license-p>Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <ext-link ext-link-type="uri" xlink:href="http://www.diabetesjournals.org/content/license">http://www.diabetesjournals.org/content/license</ext-link>.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="dc152296.pdf"></self-uri><abstract><sec><title><offsets xml_i="5191" xml_f="5200" txt_i="11" txt_f="20">OBJECTIVE</offsets></title><p><offsets xml_i="5211" xml_f="5433" txt_i="21" txt_f="243">To identify factors that predict medication adherence and to examine relationships among adherence, glycemic control, and indices of insulin action in TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth).</offsets></p></sec><sec><title><offsets xml_i="5455" xml_f="5482" txt_i="245" txt_f="272">RESEARCH DESIGN AND METHODS</offsets></title><p><offsets xml_i="5493" xml_f="6238" txt_i="273" txt_f="1015">A total of 699 youth 10–17 years old with recent-onset type 2 diabetes and ≥80% adherence to metformin therapy for ≥8 weeks during a run-in period were randomized to receive one of three treatments. Participants took two study pills twice daily. Adherence was calculated by pill count from blister packs returned at visits. High adherence was defined as taking ≥80% of medication; low adherence was defined as taking &lt;80% of medication. Depressive symptoms, insulin sensitivity (1/fasting insulin), insulinogenic index, and oral disposition index (oDI) were measured. Survival analysis examined the relationship between medication adherence and loss of glycemic control. Generalized linear mixed models analyzed trends in adherence over time.</offsets></p></sec><sec><title><offsets xml_i="6260" xml_f="6267" txt_i="1017" txt_f="1024">RESULTS</offsets></title><p><offsets xml_i="6278" xml_f="6508" txt_i="1025" txt_f="1255">In this low socioeconomic cohort, high and low adherence did not differ by sex, age, family income, parental education, or treatment group. Adherence declined over time (72% high adherence at 2 months, 56% adherence at 48 months, </offsets><italic><offsets xml_i="6516" xml_f="6517" txt_i="1255" txt_f="1256">P</offsets></italic><offsets xml_i="6526" xml_f="6670" txt_i="1256" txt_f="1397"> &lt; 0.0001). A greater percentage of participants with low adherence had clinically significant depressive symptoms at baseline (18% vs. 12%, </offsets><italic><offsets xml_i="6678" xml_f="6679" txt_i="1397" txt_f="1398">P</offsets></italic><offsets xml_i="6688" xml_f="6896" txt_i="1398" txt_f="1606"> = 0.0415). No adherence threshold predicted the loss of glycemic control. Longitudinally, participants with high adherence had significantly greater insulin sensitivity and oDI than those with low adherence.</offsets></p></sec><sec><title><offsets xml_i="6918" xml_f="6929" txt_i="1608" txt_f="1619">CONCLUSIONS</offsets></title><p><offsets xml_i="6940" xml_f="7243" txt_i="1620" txt_f="1923">In the cohort, the presence of baseline clinically significant depressive symptoms was associated with subsequent lower adherence. Medication adherence was positively associated with insulin sensitivity and oDI, but, because of disease progression, adherence did not predict long-term treatment success.</offsets></p></sec></abstract><funding-group><award-group id="sp1"><funding-source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institutes of Health (NIH)</funding-source><award-id rid="sp1">U01-DK-61212</award-id><award-id rid="sp1">U01-DK-61230</award-id><award-id rid="sp1">U01-DK-61239</award-id><award-id rid="sp1">U01-DK-61242</award-id><award-id rid="sp1">U01-DK-61254</award-id></award-group></funding-group><counts><fig-count count="2"></fig-count><table-count count="1"></table-count><equation-count count="0"></equation-count><ref-count count="47"></ref-count><page-count count="7"></page-count></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title><offsets xml_i="7960" xml_f="7972" txt_i="1932" txt_f="1944">Introduction</offsets></title><p><offsets xml_i="7983" xml_f="8156" txt_i="1945" txt_f="2118">The TODAY (Treatment Options for Type 2 Diabetes in Adolescents and Youth) clinical trial was conducted to evaluate three different treatments for type 2 diabetes in youth (</offsets><xref rid="B1" ref-type="bibr"><offsets xml_i="8187" xml_f="8188" txt_i="2118" txt_f="2119">1</offsets></xref><offsets xml_i="8195" xml_f="8421" txt_i="2119" txt_f="2342">). The results of the TODAY trial revealed that 45.6% of participants, all with recently diagnosed (&lt;2 years) youth-onset type 2 diabetes, lost glycemic control on randomized treatment usually by the end of the first year (</offsets><xref rid="B2" ref-type="bibr"><offsets xml_i="8452" xml_f="8453" txt_i="2342" txt_f="2343">2</offsets></xref><offsets xml_i="8460" xml_f="8462" txt_i="2343" txt_f="2345">).</offsets></p><p><offsets xml_i="8469" xml_f="8665" txt_i="2346" txt_f="2542">Youth in the TODAY trial were expected to take two pills twice a day. After randomization, the TODAY trial used a predetermined 80% adherence cutoff, which is commonly applied in clinical trials (</offsets><xref rid="B3" ref-type="bibr"><offsets xml_i="8696" xml_f="8697" txt_i="2542" txt_f="2543">3</offsets></xref><offsets xml_i="8704" xml_f="8790" txt_i="2543" txt_f="2629">), to monitor the adequacy of adherence to study medication during the trial. Rapoff (</offsets><xref rid="B4" ref-type="bibr"><offsets xml_i="8821" xml_f="8822" txt_i="2629" txt_f="2630">4</offsets></xref><offsets xml_i="8829" xml_f="9002" txt_i="2630" txt_f="2803">) has discussed how adherence (or lack of) can bias clinical trials of promising therapies, especially in pediatric clinical trials. Most pediatric type 1 diabetes studies (</offsets><xref rid="B5" ref-type="bibr"><offsets xml_i="9033" xml_f="9034" txt_i="2803" txt_f="2804">5</offsets></xref><offsets xml_i="9041" xml_f="9042" txt_i="2804" txt_f="2805">–</offsets><xref rid="B7" ref-type="bibr"><offsets xml_i="9073" xml_f="9074" txt_i="2805" txt_f="2806">7</offsets></xref><offsets xml_i="9081" xml_f="9228" txt_i="2806" txt_f="2953">) consistently document a correlation between adherence and race, ethnicity, and socioeconomic status, and studies of adults with type 2 diabetes (</offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="9259" xml_f="9260" txt_i="2953" txt_f="2954">8</offsets></xref><offsets xml_i="9267" xml_f="9268" txt_i="2954" txt_f="2955">,</offsets><xref rid="B9" ref-type="bibr"><offsets xml_i="9299" xml_f="9300" txt_i="2955" txt_f="2956">9</offsets></xref><offsets xml_i="9307" xml_f="9535" txt_i="2956" txt_f="3184">) have documented that depressed patients are less adherent to their diabetes regimen. There is a dearth of information in the literature regarding adherence to medication in pediatric patients with type 2 diabetes. One report (</offsets><xref rid="B10" ref-type="bibr"><offsets xml_i="9567" xml_f="9569" txt_i="3184" txt_f="3186">10</offsets></xref><offsets xml_i="9576" xml_f="9973" txt_i="3186" txt_f="3583">) from a study of youth with type 2 diabetes at three clinical sites concluded that “compliance with medications and doctor’s appointments is suboptimal in youth with type 2 diabetes.” The objective of the current analysis was to identify factors that predicted medication adherence and to examine relationships among adherence, glycemic control, and indices of insulin action in the TODAY cohort.</offsets></p></sec><sec id="s2"><title><offsets xml_i="10003" xml_f="10030" txt_i="3585" txt_f="3612">Research Design and Methods</offsets></title><sec id="s3"><title><offsets xml_i="10058" xml_f="10090" txt_i="3613" txt_f="3645">TODAY Design and Primary Results</offsets></title><p><offsets xml_i="10101" xml_f="10235" txt_i="3646" txt_f="3780">The collaborative study group included 15 clinical centers, a data coordinating center, and central laboratories and reading centers (</offsets><ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc15-2296/-/DC1"><offsets xml_i="10352" xml_f="10370" txt_i="3780" txt_f="3798">Supplementary Data</offsets></ext-link><offsets xml_i="10381" xml_f="10549" txt_i="3798" txt_f="3966">). Materials developed and used for the TODAY trial standard diabetes education program and the intensive lifestyle intervention program are available to the public at </offsets><ext-link ext-link-type="uri" xlink:href="https://today.bsc.gwu.edu"><offsets xml_i="10618" xml_f="10643" txt_i="3966" txt_f="3991">https://today.bsc.gwu.edu</offsets></ext-link><offsets xml_i="10654" xml_f="10699" txt_i="3991" txt_f="4036">/. The TODAY study design has been reported (</offsets><xref rid="B11" ref-type="bibr"><offsets xml_i="10731" xml_f="10733" txt_i="4036" txt_f="4038">11</offsets></xref><offsets xml_i="10740" xml_f="11655" txt_i="4038" txt_f="4950">) and is briefly summarized. Between July 2004 and February 2009, 699 youths between the ages of 10 and 17 years with type 2 diabetes were enrolled. To be eligible, all TODAY trial participants had to have received a diagnosis of type 2 diabetes using American Diabetes Association criteria &lt;2 years before the time of randomization; have a BMI in ≥85th percentile; and have an adult caregiver (usually the mother) who agreed to support the youth participating in the study, including accompanying the youth to all visits and helping with diabetes tasks such as medication adherence. Youths had to take ≥80% of their metformin (M) for ≥8 weeks during a run-in period in order to be eligible for randomization. A total of 927 subjects entered the run-in phase, and 699 subjects were randomized and assigned to a treatment group. Eligible participants were randomized to one of the following three treatment arms: </offsets><italic><offsets xml_i="11663" xml_f="11664" txt_i="4950" txt_f="4951">1</offsets></italic><offsets xml_i="11673" xml_f="11688" txt_i="4951" txt_f="4966">) M alone (M), </offsets><italic><offsets xml_i="11696" xml_f="11697" txt_i="4966" txt_f="4967">2</offsets></italic><offsets xml_i="11706" xml_f="11740" txt_i="4967" txt_f="5001">) M plus rosiglitazone (M+R), and </offsets><italic><offsets xml_i="11748" xml_f="11749" txt_i="5001" txt_f="5002">3</offsets></italic><offsets xml_i="11758" xml_f="11962" txt_i="5002" txt_f="5206">) M plus an intensive lifestyle program (M+L). The primary objective of the TODAY trial was to compare the three arms on time to treatment failure (i.e., loss of glycemic control, defined as either an HbA</offsets><sub><offsets xml_i="11967" xml_f="11969" txt_i="5206" txt_f="5208">1c</offsets></sub><offsets xml_i="11975" xml_f="12258" txt_i="5208" txt_f="5491"> level of ≥8% over a 6-month period or an inability to wean from temporary insulin therapy within 3 months after acute metabolic decompensation). After an average follow-up period of 3.9 years, 319 subjects (45.6%) reached the primary outcome; the M+R arm was superior to the M arm (</offsets><italic><offsets xml_i="12266" xml_f="12267" txt_i="5491" txt_f="5492">P</offsets></italic><offsets xml_i="12276" xml_f="12350" txt_i="5492" txt_f="5566"> = 0.006), and the M+L arm was intermediate but not different from M arm (</offsets><xref rid="B2" ref-type="bibr"><offsets xml_i="12381" xml_f="12382" txt_i="5566" txt_f="5567">2</offsets></xref><offsets xml_i="12389" xml_f="12391" txt_i="5567" txt_f="5569">).</offsets></p></sec><sec id="s4"><title><offsets xml_i="12421" xml_f="12458" txt_i="5571" txt_f="5608">Study Medication Adherence Procedures</offsets></title><p><offsets xml_i="12469" xml_f="12823" txt_i="5609" txt_f="5963">The dose for all treatment arms was two capsules twice daily. Masked study drug (M or M+R) was provided in 7-day blister packs separated into morning and evening two-pill doses. M and R were encapsulated together. All pills looked, smelled, and tasted the same. Study subjects were instructed to return all blister packs at their regular study visit. HbA</offsets><sub><offsets xml_i="12828" xml_f="12830" txt_i="5963" txt_f="5965">1c</offsets></sub><offsets xml_i="12836" xml_f="12978" txt_i="5965" txt_f="6107"> values were partially masked to the subject and the investigators. Investigators were not informed of the value, but were notified if the HbA</offsets><sub><offsets xml_i="12983" xml_f="12985" txt_i="6107" txt_f="6109">1c</offsets></sub><offsets xml_i="12991" xml_f="13041" txt_i="6109" txt_f="6159"> level was on target, stable, rising, or elevated.</offsets></p><p><offsets xml_i="13048" xml_f="13877" txt_i="6160" txt_f="6983">For this analysis, adherence was measured while study subjects received randomized treatment (i.e., prior to the primary outcome [loss of glycemic control] or at the end of the study visit). Collection of adherence data (pill counts) and dispensing of the study drug occurred at each study visit (every 2 months in year 1 and then quarterly). Adherence was calculated as the percentage of the prescribed study drug taken, based on pill counts. If pill packs (empty, partial, or full) were not returned at a visit as instructed, then adherence could not be determined and was noted as missing. Adherence could be &gt;100% if the number of pills taken based on empty containers brought to a visit was greater than the prescribed four pills per day. Outlier values were examined, and values &gt;110% were excluded from the analysis.</offsets></p><p><offsets xml_i="13884" xml_f="15043" txt_i="6984" txt_f="8140">At each visit, study staff evaluated and discussed adherence with the participant. There was no standardized behavioral intervention to address adherence. Based on adherence barriers identified in discussion with the participant and caregiver, study personnel worked with the participant on strategies to increase medication adherence. Participants could earn “points” for goal attainment, including medication adherence of ≥80%. Participants could earn up to 12 points per month (6 points for 100% medication adherence, 5 points for 90–99% adherence, or 4 points for 80–89% adherence; 3 points for glucose monitoring; 2 points for bringing back blister packs and a logbook to a visit; and 1 point for setting goals at the visit). Subjects who had &lt;80% adherence did not earn points for medication adherence. Accumulated points could be exchanged for incentive items worth up to $150 per year. Adherence was monitored by the study group committees on Procedures Oversight and Retention and Adherence. Clinical centers below a target cutoff of 80% were contacted to address problems and provide support on both participant-specific and site-specific levels.</offsets></p></sec><sec id="s5"><title><offsets xml_i="15073" xml_f="15093" txt_i="8142" txt_f="8162">Factors and Measures</offsets></title><p><offsets xml_i="15104" xml_f="15913" txt_i="8163" txt_f="8972">Race-ethnicity was determined by self-report. Participants were categorized as non-Hispanic black, non-Hispanic white, or Hispanic; categories that were too small for separate analysis were combined into Other (7%) and were not included in analyses by race-ethnicity. Household education was the highest education level attained by the parent/guardian; 15 education categories were collapsed into 4 for purposes of analysis. The annual household income of all persons living in the household in the past year was collected by self-report of family members present at the baseline visit; nine categories were collapsed into three for purposes of analysis. Percentage overweight, the recommended outcome for reporting changes in adiposity in youth, was calculated as percentage over median BMI for age and sex (</offsets><xref rid="B12" ref-type="bibr"><offsets xml_i="15945" xml_f="15947" txt_i="8972" txt_f="8974">12</offsets></xref><offsets xml_i="15954" xml_f="15955" txt_i="8974" txt_f="8975">–</offsets><xref rid="B14" ref-type="bibr"><offsets xml_i="15987" xml_f="15989" txt_i="8975" txt_f="8977">14</offsets></xref><offsets xml_i="15996" xml_f="16158" txt_i="8977" txt_f="9139">). Health-related quality of life was measured by youth self-report on the generic scale (PedsQL 3.0) with impaired quality of life defined at a cutoff of 71.19 (</offsets><xref rid="B15" ref-type="bibr"><offsets xml_i="16190" xml_f="16192" txt_i="9139" txt_f="9141">15</offsets></xref><offsets xml_i="16199" xml_f="16386" txt_i="9141" txt_f="9325">). Depressive symptoms were assessed using either the Children’s Depression Inventory for participants &lt;16 years of age or the Beck Depression Inventory II for those ≥16 years of age (</offsets><xref rid="B16" ref-type="bibr"><offsets xml_i="16418" xml_f="16420" txt_i="9325" txt_f="9327">16</offsets></xref><offsets xml_i="16427" xml_f="16428" txt_i="9327" txt_f="9328">,</offsets><xref rid="B17" ref-type="bibr"><offsets xml_i="16460" xml_f="16462" txt_i="9328" txt_f="9330">17</offsets></xref><offsets xml_i="16469" xml_f="16939" txt_i="9330" txt_f="9800">). Total scores were calculated for each instrument; a cutoff score ≥13 on the Children’s Depression Inventory and ≥14 on the Beck Depression Inventory II indicated clinically significant depressive symptoms. The TODAY trial primary outcome, time to treatment failure, indicated durability of glycemic control. Three measures of insulin secretion/sensitivity were derived from the oral glucose tolerance test. Insulin sensitivity was calculated as 1/fasting insulin (1/I</offsets><sub><offsets xml_i="16944" xml_f="16945" txt_i="9800" txt_f="9801">F</offsets></sub><offsets xml_i="16951" xml_f="17143" txt_i="9801" txt_f="9993">), also called the insulin inverse; this measure correlates strongly with hyperinsulinemic-euglycemic clamp–derived in vivo insulin sensitivity in obese youth with or without type 2 diabetes (</offsets><xref rid="B18" ref-type="bibr"><offsets xml_i="17175" xml_f="17177" txt_i="9993" txt_f="9995">18</offsets></xref><offsets xml_i="17184" xml_f="17315" txt_i="9995" txt_f="10126">). The insulinogenic index was calculated as the ratio of the incremental insulin and glucose responses from baseline to 30 min (△I</offsets><sub><offsets xml_i="17320" xml_f="17322" txt_i="10126" txt_f="10128">30</offsets></sub><offsets xml_i="17328" xml_f="17331" txt_i="10128" txt_f="10131">/△G</offsets><sub><offsets xml_i="17336" xml_f="17338" txt_i="10131" txt_f="10133">30</offsets></sub><offsets xml_i="17344" xml_f="17347" txt_i="10133" txt_f="10136">) (</offsets><xref rid="B19" ref-type="bibr"><offsets xml_i="17379" xml_f="17381" txt_i="10136" txt_f="10138">19</offsets></xref><offsets xml_i="17388" xml_f="17532" txt_i="10138" txt_f="10282">). This index reflects similar trends in first-phase insulin from the hyperglycemic clamp in obese youth across the glucose tolerance spectrum (</offsets><xref rid="B18" ref-type="bibr"><offsets xml_i="17564" xml_f="17566" txt_i="10282" txt_f="10284">18</offsets></xref><offsets xml_i="17573" xml_f="17767" txt_i="10284" txt_f="10478">). The oral disposition index (oDI), a measure of β-cell function relative to insulin sensitivity, was calculated as the product of insulin sensitivity multiplied by the insulinogenic index (1/I</offsets><sub><offsets xml_i="17772" xml_f="17773" txt_i="10478" txt_f="10479">F</offsets></sub><offsets xml_i="17779" xml_f="17784" txt_i="10479" txt_f="10484"> × △I</offsets><sub><offsets xml_i="17789" xml_f="17791" txt_i="10484" txt_f="10486">30</offsets></sub><offsets xml_i="17797" xml_f="17800" txt_i="10486" txt_f="10489">/△G</offsets><sub><offsets xml_i="17805" xml_f="17807" txt_i="10489" txt_f="10491">30</offsets></sub><offsets xml_i="17813" xml_f="18158" txt_i="10491" txt_f="10836">); in obese youth as well as adults, the oDI correlates strongly with clamp-derived disposition index (DI), identifies comparable decrements in β-cell function across the glucose tolerance groups (as does the clamp DI), and has analogous predictive power to that of clamp DI for the 2-h glucose concentration of the oral glucose tolerance test (</offsets><xref rid="B19" ref-type="bibr"><offsets xml_i="18190" xml_f="18192" txt_i="10836" txt_f="10838">19</offsets></xref><offsets xml_i="18199" xml_f="18200" txt_i="10838" txt_f="10839">,</offsets><xref rid="B20" ref-type="bibr"><offsets xml_i="18232" xml_f="18234" txt_i="10839" txt_f="10841">20</offsets></xref><offsets xml_i="18241" xml_f="18243" txt_i="10841" txt_f="10843">).</offsets></p></sec><sec id="s6"><title><offsets xml_i="18273" xml_f="18293" txt_i="10845" txt_f="10865">Statistical Analysis</offsets></title><p><offsets xml_i="18304" xml_f="18716" txt_i="10866" txt_f="11278">Study medication adherence is typically analyzed as a categorical or dichotomous variable; the continuous distribution was not appropriate even with transformation. Therefore, to be practically useful, a cutoff defining “adequate dose” (i.e., adequate to have the intended effect) is identified for monitoring purposes. The TODAY trial used a preplanned 80% cutoff, which is commonly applied in clinical trials (</offsets><xref rid="B3" ref-type="bibr"><offsets xml_i="18747" xml_f="18748" txt_i="11278" txt_f="11279">3</offsets></xref><offsets xml_i="18755" xml_f="19298" txt_i="11279" txt_f="11822">) to assess the adequacy of adherence during the trial. The effect of adherence on treatment failure was analyzed using time-to-event survival methods, where time was entered as an interval for those who failed, and adherence and the interaction between adherence and treatment group were included in the model. The analysis was repeated for adherence cutoffs at 60%, 70%, and 90% adherence to determine whether there was a threshold effect. Tests of association between adherence and demographic and baseline characteristics used either the χ</offsets><sup><offsets xml_i="19303" xml_f="19304" txt_i="11822" txt_f="11823">2</offsets></sup><offsets xml_i="19310" xml_f="19655" txt_i="11823" txt_f="12168"> test (for categorical characteristics) or ANOVA (for continuous variables). Generalized linear mixed models were used to compare adherence across treatment groups and over time. Study medication adherence cutoffs were applied to mean adherence prior to treatment failure, while the participant was still receiving the assigned study medication.</offsets></p><p><offsets xml_i="19662" xml_f="20061" txt_i="12169" txt_f="12568">Measures of insulin secretion/sensitivity (insulin sensitivity, insulinogenic index, and oDI) were analyzed in models including time (visit number), study medication adherence, and their interaction, with a baseline measure of insulin secretion/sensitivity as a covariate. All measures of insulin secretion/sensitivity were log transformed to normalize the distribution. Significance was defined as </offsets><italic><offsets xml_i="20069" xml_f="20070" txt_i="12568" txt_f="12569">P</offsets></italic><offsets xml_i="20079" xml_f="20182" txt_i="12569" txt_f="12669"> &lt; 0.05 with no adjustment for multiple testing; the trial was powered for the primary outcome only.</offsets></p></sec></sec><sec sec-type="results" id="s7"><title><offsets xml_i="20237" xml_f="20244" txt_i="12672" txt_f="12679">Results</offsets></title><sec id="s8"><title><offsets xml_i="20272" xml_f="20312" txt_i="12680" txt_f="12720">Adherence Across Time by Treatment Group</offsets></title><p><offsets xml_i="20323" xml_f="20527" txt_i="12721" txt_f="12925">Of the 699 subjects in the TODAY cohort, 42 were not included in the analysis (8 never returned after the baseline visit, and 34 reached the primary study outcome within the first 5 months of the study). </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="20557" xml_f="20565" txt_i="12925" txt_f="12933">Figure 1</offsets></xref><offsets xml_i="20572" xml_f="20798" txt_i="12933" txt_f="13159"> plots the percentage of subjects with adequate study drug adherence (using the 80% cutoff) across time (months 2–48) by treatment group. As seen, overall adherence declined as a function of the number of months in the study (</offsets><italic><offsets xml_i="20806" xml_f="20807" txt_i="13159" txt_f="13160">P</offsets></italic><offsets xml_i="20816" xml_f="20997" txt_i="13160" txt_f="13338"> &lt; 0.0001) but was not different across treatment groups. When the analysis was repeated for adherence cutoffs at 60%, 70%, and 90%, results were similar to 80% (data not shown).</offsets></p><fig id="F1" fig-type="figure" orientation="portrait" position="float"><label><offsets xml_i="21079" xml_f="21087" txt_i="13339" txt_f="13347">Figure 1</offsets></label><caption><p><offsets xml_i="21107" xml_f="21324" txt_i="13347" txt_f="13564">Data are shown through follow-up month 48. All data are from prior to treatment failure when participants were placed on a uniform diabetes management regimen. Adherence to medication significantly dropped over time (</offsets><italic><offsets xml_i="21332" xml_f="21333" txt_i="13564" txt_f="13565">P</offsets></italic><offsets xml_i="21342" xml_f="21410" txt_i="13565" txt_f="13630"> &lt; 0.0001), but there were no differences among treatment groups.</offsets></p></caption><graphic xlink:href="dc152296f1"></graphic></fig></sec><sec id="s9"><title><offsets xml_i="21499" xml_f="21532" txt_i="13632" txt_f="13665">Factors Associated With Adherence</offsets></title><p><offsets xml_i="21543" xml_f="21622" txt_i="13666" txt_f="13745">Baseline data and demographic characteristics by adherence status are shown in </offsets><xref ref-type="table" rid="T1"><offsets xml_i="21654" xml_f="21661" txt_i="13745" txt_f="13752">Table 1</offsets></xref><offsets xml_i="21668" xml_f="22108" txt_i="13752" txt_f="14192">. For each participant, average adherence over time on randomized treatment was dichotomized at the 80% cutoff used during the study to monitor adequate adherence. Participants reporting clinically significant depressive symptoms at baseline were more likely to be in the lower-adherence group. Key characteristics that were not significant included sex, race-ethnicity, determinants of socioeconomic status, and randomized treatment group.</offsets></p><table-wrap id="T1" orientation="portrait" position="float"><label><offsets xml_i="22179" xml_f="22186" txt_i="14193" txt_f="14200">Table 1</offsets></label><caption><p><offsets xml_i="22206" xml_f="22274" txt_i="14200" txt_f="14268">Baseline and demographic characteristics by overall adherence status</offsets></p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th align="left" scope="col" rowspan="1" colspan="1"><offsets xml_i="22405" xml_f="22420" txt_i="14269" txt_f="14284">Characteristics</offsets></th><th align="center" scope="col" rowspan="1" colspan="1"><offsets xml_i="22480" xml_f="22484" txt_i="14284" txt_f="14288">All(</offsets><italic><offsets xml_i="22492" xml_f="22493" txt_i="14288" txt_f="14289">n</offsets></italic><offsets xml_i="22502" xml_f="22509" txt_i="14289" txt_f="14296"> = 657)</offsets></th><th align="center" scope="col" rowspan="1" colspan="1"><offsets xml_i="22569" xml_f="22577" txt_i="14296" txt_f="14301">&lt;80%(</offsets><italic><offsets xml_i="22585" xml_f="22586" txt_i="14301" txt_f="14302">n</offsets></italic><offsets xml_i="22595" xml_f="22607" txt_i="14302" txt_f="14314"> = 292, 44%)</offsets></th><th align="center" scope="col" rowspan="1" colspan="1"><offsets xml_i="22667" xml_f="22672" txt_i="14314" txt_f="14319">≥80%(</offsets><italic><offsets xml_i="22680" xml_f="22681" txt_i="14319" txt_f="14320">n</offsets></italic><offsets xml_i="22690" xml_f="22702" txt_i="14320" txt_f="14332"> = 365, 56%)</offsets></th><th align="center" scope="col" rowspan="1" colspan="1"><italic><offsets xml_i="22770" xml_f="22771" txt_i="14332" txt_f="14333">P</offsets></italic><offsets xml_i="22780" xml_f="22786" txt_i="14333" txt_f="14339"> value</offsets></th></tr></thead><tbody><tr><td align="left" scope="row" rowspan="1" colspan="1"><offsets xml_i="22868" xml_f="22879" txt_i="14339" txt_f="14350">Age (years)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="22927" xml_f="22937" txt_i="14351" txt_f="14361">14.0 (2.0)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="22985" xml_f="22995" txt_i="14362" txt_f="14372">14.1 (1.9)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="23043" xml_f="23053" txt_i="14373" txt_f="14383">13.9 (2.1)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="23101" xml_f="23107" txt_i="14384" txt_f="14390">0.2809</offsets></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><offsets xml_i="23174" xml_f="23177" txt_i="14391" txt_f="14394">Sex</offsets></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="23363" xml_f="23369" txt_i="14398" txt_f="14404">0.8418</offsets></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><offsets xml_i="23436" xml_f="23443" txt_i="14405" txt_f="14412"> Female</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="23491" xml_f="23502" txt_i="14413" txt_f="14424">419 (63.8%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="23550" xml_f="23561" txt_i="14425" txt_f="14436">185 (63.4%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="23609" xml_f="23620" txt_i="14437" txt_f="14448">234 (64.1%)</offsets></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><offsets xml_i="23733" xml_f="23738" txt_i="14450" txt_f="14455"> Male</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="23786" xml_f="23797" txt_i="14456" txt_f="14467">238 (36.2%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="23845" xml_f="23856" txt_i="14468" txt_f="14479">107 (36.6%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="23904" xml_f="23915" txt_i="14480" txt_f="14491">131 (35.9%)</offsets></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><offsets xml_i="24028" xml_f="24042" txt_i="14493" txt_f="14507">Race-ethnicity</offsets><xref ref-type="table-fn" rid="t1n1"><offsets xml_i="24079" xml_f="24080" txt_i="14507" txt_f="14508">†</offsets></xref></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="24273" xml_f="24279" txt_i="14512" txt_f="14518">0.1036</offsets></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><offsets xml_i="24346" xml_f="24365" txt_i="14519" txt_f="14538"> Black non-Hispanic</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="24413" xml_f="24424" txt_i="14539" txt_f="14550">209 (34.4%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="24472" xml_f="24482" txt_i="14551" txt_f="14561">95 (36.0%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="24530" xml_f="24541" txt_i="14562" txt_f="14573">114 (33.1%)</offsets></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><offsets xml_i="24654" xml_f="24663" txt_i="14575" txt_f="14584"> Hispanic</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="24711" xml_f="24722" txt_i="14585" txt_f="14596">266 (43.7%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="24770" xml_f="24781" txt_i="14597" txt_f="14608">122 (46.2%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="24829" xml_f="24840" txt_i="14609" txt_f="14620">144 (41.9%)</offsets></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><offsets xml_i="24953" xml_f="24972" txt_i="14622" txt_f="14641"> White non-Hispanic</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="25020" xml_f="25031" txt_i="14642" txt_f="14653">133 (21.9%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="25079" xml_f="25089" txt_i="14654" txt_f="14664">47 (17.8%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="25137" xml_f="25147" txt_i="14665" txt_f="14675">86 (25.0%)</offsets></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><offsets xml_i="25260" xml_f="25287" txt_i="14677" txt_f="14704">Highest household education</offsets></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="25473" xml_f="25479" txt_i="14708" txt_f="14714">0.9894</offsets></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><offsets xml_i="25546" xml_f="25568" txt_i="14715" txt_f="14737"> Less than high school</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="25616" xml_f="25627" txt_i="14738" txt_f="14749">173 (26.8%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="25675" xml_f="25685" txt_i="14750" txt_f="14760">76 (26.5%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="25733" xml_f="25743" txt_i="14761" txt_f="14771">97 (27.0%)</offsets></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><offsets xml_i="25856" xml_f="25903" txt_i="14773" txt_f="14820"> High school, GED, business or technical school</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="25951" xml_f="25962" txt_i="14821" txt_f="14832">159 (24.6%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="26010" xml_f="26020" txt_i="14833" txt_f="14843">71 (24.7%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="26068" xml_f="26078" txt_i="14844" txt_f="14854">88 (24.5%)</offsets></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><offsets xml_i="26191" xml_f="26209" txt_i="14856" txt_f="14874"> College no degree</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="26257" xml_f="26268" txt_i="14875" txt_f="14886">207 (32.0%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="26316" xml_f="26326" txt_i="14887" txt_f="14897">91 (31.7%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="26374" xml_f="26385" txt_i="14898" txt_f="14909">116 (32.3%)</offsets></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><offsets xml_i="26498" xml_f="26514" txt_i="14911" txt_f="14927"> Graduate degree</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="26562" xml_f="26573" txt_i="14928" txt_f="14939">107 (16.6%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="26621" xml_f="26631" txt_i="14940" txt_f="14950">49 (17.1%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="26679" xml_f="26689" txt_i="14951" txt_f="14961">58 (16.2%)</offsets></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><offsets xml_i="26802" xml_f="26825" txt_i="14963" txt_f="14986">Annual household income</offsets></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="27011" xml_f="27017" txt_i="14990" txt_f="14996">0.2510</offsets></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><offsets xml_i="27084" xml_f="27096" txt_i="14997" txt_f="15006"> &lt;$25,000</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="27144" xml_f="27155" txt_i="15007" txt_f="15018">243 (41.2%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="27203" xml_f="27214" txt_i="15019" txt_f="15030">114 (44.5%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="27262" xml_f="27273" txt_i="15031" txt_f="15042">129 (38.6%)</offsets></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><offsets xml_i="27386" xml_f="27401" txt_i="15044" txt_f="15059"> $25,000–49,999</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="27449" xml_f="27460" txt_i="15060" txt_f="15071">201 (34.1%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="27508" xml_f="27518" txt_i="15072" txt_f="15082">86 (33.6%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="27566" xml_f="27577" txt_i="15083" txt_f="15094">115 (34.4%)</offsets></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><offsets xml_i="27690" xml_f="27699" txt_i="15096" txt_f="15105"> ≥$50,000</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="27747" xml_f="27758" txt_i="15106" txt_f="15117">146 (24.7%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="27806" xml_f="27816" txt_i="15118" txt_f="15128">56 (21.9%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="27864" xml_f="27874" txt_i="15129" txt_f="15139">90 (27.0%)</offsets></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><offsets xml_i="27987" xml_f="27996" txt_i="15141" txt_f="15150">BMI (kg/m</offsets><sup><offsets xml_i="28001" xml_f="28002" txt_i="15150" txt_f="15151">2</offsets></sup><offsets xml_i="28008" xml_f="28009" txt_i="15151" txt_f="15152">)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="28057" xml_f="28067" txt_i="15153" txt_f="15163">34.9 (7.6)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="28115" xml_f="28125" txt_i="15164" txt_f="15174">35.5 (7.9)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="28173" xml_f="28183" txt_i="15175" txt_f="15185">34.4 (7.3)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="28231" xml_f="28237" txt_i="15186" txt_f="15192">0.0681</offsets></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><offsets xml_i="28304" xml_f="28308" txt_i="15193" txt_f="15197">BMI </offsets><italic><offsets xml_i="28316" xml_f="28317" txt_i="15197" txt_f="15198">z</offsets></italic><offsets xml_i="28326" xml_f="28332" txt_i="15198" txt_f="15204">-score</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="28380" xml_f="28391" txt_i="15205" txt_f="15216">2.23 (0.46)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="28439" xml_f="28450" txt_i="15217" txt_f="15228">2.26 (0.44)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="28498" xml_f="28509" txt_i="15229" txt_f="15240">2.20 (0.48)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="28557" xml_f="28563" txt_i="15241" txt_f="15247">0.1102</offsets></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><offsets xml_i="28630" xml_f="28644" txt_i="15248" txt_f="15262">Overweight (%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="28692" xml_f="28703" txt_i="15263" txt_f="15274">78.9 (37.0)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="28751" xml_f="28762" txt_i="15275" txt_f="15286">81.3 (39.4)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="28810" xml_f="28821" txt_i="15287" txt_f="15298">77.0 (34.9)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="28869" xml_f="28875" txt_i="15299" txt_f="15305">0.1342</offsets></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><offsets xml_i="28942" xml_f="28956" txt_i="15306" txt_f="15320">Impaired HRQOL</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="29004" xml_f="29015" txt_i="15321" txt_f="15332">146 (22.6%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="29063" xml_f="29073" txt_i="15333" txt_f="15343">72 (24.9%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="29121" xml_f="29131" txt_i="15344" txt_f="15354">74 (20.7%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="29179" xml_f="29185" txt_i="15355" txt_f="15361">0.2060</offsets></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><offsets xml_i="29252" xml_f="29271" txt_i="15362" txt_f="15381">Depressive symptoms</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="29319" xml_f="29329" txt_i="15382" txt_f="15392">93 (14.5%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="29377" xml_f="29387" txt_i="15393" txt_f="15403">50 (17.7%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="29435" xml_f="29445" txt_i="15404" txt_f="15414">43 (12.0%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="29493" xml_f="29499" txt_i="15415" txt_f="15421">0.0415</offsets></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><offsets xml_i="29566" xml_f="29581" txt_i="15422" txt_f="15437">Treatment group</offsets></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="29767" xml_f="29773" txt_i="15441" txt_f="15447">0.2726</offsets></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><offsets xml_i="29840" xml_f="29842" txt_i="15448" txt_f="15450"> M</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="29890" xml_f="29901" txt_i="15451" txt_f="15462">218 (33.2%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="29949" xml_f="29959" txt_i="15463" txt_f="15473">88 (30.1%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="30007" xml_f="30018" txt_i="15474" txt_f="15485">130 (35.6%)</offsets></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><offsets xml_i="30131" xml_f="30135" txt_i="15487" txt_f="15491"> M+R</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="30183" xml_f="30194" txt_i="15492" txt_f="15503">218 (33.2%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="30242" xml_f="30252" txt_i="15504" txt_f="15514">98 (33.6%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="30300" xml_f="30311" txt_i="15515" txt_f="15526">120 (32.9%)</offsets></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" scope="row" rowspan="1" colspan="1"><offsets xml_i="30424" xml_f="30428" txt_i="15528" txt_f="15532"> M+L</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="30476" xml_f="30487" txt_i="15533" txt_f="15544">221 (33.6%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="30535" xml_f="30546" txt_i="15545" txt_f="15556">106 (36.3%)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="30594" xml_f="30605" txt_i="15557" txt_f="15568">115 (31.5%)</offsets></td><td align="left" rowspan="1" colspan="1"></td></tr></tbody></table><table-wrap-foot><fn><p><offsets xml_i="30701" xml_f="30746" txt_i="15570" txt_f="15615">The values were reported as the mean (SD) or </offsets><italic><offsets xml_i="30754" xml_f="30755" txt_i="15615" txt_f="15616">n</offsets></italic><offsets xml_i="30764" xml_f="30836" txt_i="15616" txt_f="15688"> (%), unless otherwise indicated. HRQOL, health-related quality of life.</offsets></p></fn><fn id="t1n1"><p><offsets xml_i="30862" xml_f="30915" txt_i="15689" txt_f="15742">†Only the major three racial/ethnic groups are shown.</offsets></p></fn></table-wrap-foot></table-wrap></sec><sec id="s10"><title><offsets xml_i="30982" xml_f="31012" txt_i="15744" txt_f="15774">Durability of Glycemic Control</offsets></title><p><offsets xml_i="31023" xml_f="31423" txt_i="15775" txt_f="16175">We examined the TODAY trial primary outcome (time-to-failure analysis) with adherence status. The model included the interaction between adherence status and treatment group. The analysis was performed for adherence cutoffs at 60%, 70%, 80%, and 90%. At all four adherence cutoffs, the results by treatment group were similar to the results for 80% adherence reported in the primary outcome article (</offsets><xref rid="B2" ref-type="bibr"><offsets xml_i="31454" xml_f="31455" txt_i="16175" txt_f="16176">2</offsets></xref><offsets xml_i="31462" xml_f="31792" txt_i="16176" txt_f="16506">) (i.e., the only significant treatment group comparison was M vs. M+R). Failure was not associated with lower adherence to taking medication. Among those subjects who failed therapy, 62.5% had at least an 80% adherence to study medication on average compared with 50.3% in those who did not fail therapy by the end of the study (</offsets><italic><offsets xml_i="31800" xml_f="31801" txt_i="16506" txt_f="16507">P</offsets></italic><offsets xml_i="31810" xml_f="31821" txt_i="16507" txt_f="16518"> = 0.0018).</offsets></p></sec><sec id="s11"><title><offsets xml_i="31852" xml_f="31881" txt_i="16520" txt_f="16549">Insulin Secretion/Sensitivity</offsets></title><p><xref ref-type="fig" rid="F2"><offsets xml_i="31922" xml_f="31930" txt_i="16550" txt_f="16558">Figure 2</offsets></xref><offsets xml_i="31937" xml_f="32042" txt_i="16558" txt_f="16663"> shows longitudinal data at 6, 24, 36, and 48 months postrandomization and prior to glycemic failure for </offsets><italic><offsets xml_i="32050" xml_f="32051" txt_i="16663" txt_f="16664">1</offsets></italic><offsets xml_i="32060" xml_f="32086" txt_i="16664" txt_f="16690">) insulin sensitivity and </offsets><italic><offsets xml_i="32094" xml_f="32095" txt_i="16690" txt_f="16691">2</offsets></italic><xref ref-type="fig" rid="F2"><offsets xml_i="32134" xml_f="32140" txt_i="16691" txt_f="16697">Fig. 2</offsets><italic><offsets xml_i="32148" xml_f="32149" txt_i="16697" txt_f="16698">A</offsets></italic></xref><offsets xml_i="32165" xml_f="32168" txt_i="16698" txt_f="16701">) (</offsets><italic><offsets xml_i="32176" xml_f="32177" txt_i="16701" txt_f="16702">P</offsets></italic><offsets xml_i="32186" xml_f="32213" txt_i="16702" txt_f="16729"> = 0.0012) and higher oDI (</offsets><italic><offsets xml_i="32221" xml_f="32222" txt_i="16729" txt_f="16730">P</offsets></italic><offsets xml_i="32231" xml_f="32277" txt_i="16730" txt_f="16776"> = 0.0248), but not with insulinogenic index (</offsets><xref ref-type="fig" rid="F2"><offsets xml_i="32307" xml_f="32313" txt_i="16776" txt_f="16782">Fig. 2</offsets><italic><offsets xml_i="32321" xml_f="32322" txt_i="16782" txt_f="16783">B</offsets></italic></xref><offsets xml_i="32338" xml_f="32341" txt_i="16783" txt_f="16786">) (</offsets><italic><offsets xml_i="32349" xml_f="32350" txt_i="16786" txt_f="16787">P</offsets></italic><offsets xml_i="32359" xml_f="32440" txt_i="16787" txt_f="16868"> = 0.4733). There was a significant trend over time for the insulinogenic index (</offsets><italic><offsets xml_i="32448" xml_f="32449" txt_i="16868" txt_f="16869">P</offsets></italic><offsets xml_i="32458" xml_f="32478" txt_i="16869" txt_f="16889"> = 0.0076) and oDI (</offsets><italic><offsets xml_i="32486" xml_f="32487" txt_i="16889" txt_f="16890">P</offsets></italic><offsets xml_i="32496" xml_f="32533" txt_i="16890" txt_f="16927"> = 0.0307), but not insulin inverse (</offsets><italic><offsets xml_i="32541" xml_f="32542" txt_i="16927" txt_f="16928">P</offsets></italic><offsets xml_i="32551" xml_f="32689" txt_i="16928" txt_f="17066"> = 0.1291). Analysis of medication adherence at other adherence cutoffs revealed similar relationships with insulin secretion/sensitivity.</offsets></p><fig id="F2" fig-type="figure" orientation="portrait" position="float"><label><offsets xml_i="32771" xml_f="32779" txt_i="17067" txt_f="17075">Figure 2</offsets></label><caption><p><offsets xml_i="32799" xml_f="32912" txt_i="17075" txt_f="17188">Data are from prior to treatment failure when participants were placed on a uniform diabetes management regimen. </offsets><italic><offsets xml_i="32920" xml_f="32921" txt_i="17188" txt_f="17189">A</offsets></italic><offsets xml_i="32930" xml_f="33090" txt_i="17189" txt_f="17349">: For insulin inverse, there was a significant difference between the adherence groups (i.e., the higher-adherence group had higher values of insulin inverse) (</offsets><italic><offsets xml_i="33098" xml_f="33099" txt_i="17349" txt_f="17350">P</offsets></italic><offsets xml_i="33108" xml_f="33200" txt_i="17350" txt_f="17442"> = 0.0012), but the lines were parallel (no interaction) and flat (no visit or time trend). </offsets><italic><offsets xml_i="33208" xml_f="33209" txt_i="17442" txt_f="17443">B</offsets></italic><offsets xml_i="33218" xml_f="33295" txt_i="17443" txt_f="17520">: For the insulinogenic index, there was a significant difference over time (</offsets><italic><offsets xml_i="33303" xml_f="33304" txt_i="17520" txt_f="17521">P</offsets></italic><offsets xml_i="33313" xml_f="33406" txt_i="17521" txt_f="17614"> = 0.0076), and a rise at month 36 was detected, which was the same in both adherence groups.</offsets></p></caption><graphic xlink:href="dc152296f2"></graphic></fig></sec></sec><sec sec-type="conclusions" id="s12"><title><offsets xml_i="33525" xml_f="33536" txt_i="17617" txt_f="17628">Conclusions</offsets></title><p><offsets xml_i="33547" xml_f="33893" txt_i="17629" txt_f="17975">The TODAY cohort demonstrated deterioration in study medication adherence over time, irrespective of treatment group assignment. Paradoxically, the current analysis found that those who reached the primary outcome actually had higher adherence levels than those who did not reach the primary outcome. Possible explanations include the following: </offsets><italic><offsets xml_i="33901" xml_f="33902" txt_i="17975" txt_f="17976">1</offsets></italic><offsets xml_i="33911" xml_f="34001" txt_i="17976" txt_f="18066">) patients who notice high glucose readings were more likely to take their medication and </offsets><italic><offsets xml_i="34009" xml_f="34010" txt_i="18066" txt_f="18067">2</offsets></italic><offsets xml_i="34019" xml_f="34155" txt_i="18067" txt_f="18203">) clinicians emphasized medication adherence more strongly and more frequently with participants whose blood glucose levels were higher.</offsets></p><p><offsets xml_i="34162" xml_f="35076" txt_i="18204" txt_f="19112">Contrary to expectation, demographic factors (sex, race-ethnicity, household income, and parental educational level) did not predict medication adherence. The lack of correlation with these factors in the TODAY trial may be explained by the limited income and educational range of the families in the TODAY trial. Nearly half of the families in the TODAY trial had an annual income of &lt;$25,000, and, for over half of the families, the highest level of parental education was a high school degree or lower. In addition, our run-in criteria selected for more adherent subjects. All subjects had to have &gt;80% adherence to M therapy for ≥8 weeks before they could be randomized. This may have limited variability in medication adherence postrandomization. It is also possible that selecting for more adherent subjects in the run-in period also selected for subjects with a lower frequency of depressive symptoms.</offsets></p><p><offsets xml_i="35083" xml_f="35465" txt_i="19113" txt_f="19495">In the TODAY trial, baseline clinically significant depressive symptoms were more prevalent in the lower-adherence group, suggesting that regular screening for depressive symptoms should be undertaken to identify youth who were at high risk for poor medication adherence. In the TODAY study sample, ∼15% scored at or above the cutoff for clinically significant depressive symptoms (</offsets><xref rid="B21" ref-type="bibr"><offsets xml_i="35497" xml_f="35499" txt_i="19495" txt_f="19497">21</offsets></xref><offsets xml_i="35506" xml_f="35574" txt_i="19497" txt_f="19565">). These results are similar to those reported in the SEARCH study (</offsets><xref rid="B22" ref-type="bibr"><offsets xml_i="35606" xml_f="35608" txt_i="19565" txt_f="19567">22</offsets></xref><offsets xml_i="35615" xml_f="35845" txt_i="19567" txt_f="19797">), which found that being female and of older age were risk factors for higher rates of clinically significant depressive symptoms in a pediatric sample of individuals with type 2 diabetes. Studies in adults with type 2 diabetes (</offsets><xref rid="B23" ref-type="bibr"><offsets xml_i="35877" xml_f="35879" txt_i="19797" txt_f="19799">23</offsets></xref><offsets xml_i="35886" xml_f="35887" txt_i="19799" txt_f="19800">–</offsets><xref rid="B28" ref-type="bibr"><offsets xml_i="35919" xml_f="35921" txt_i="19800" txt_f="19802">28</offsets></xref><offsets xml_i="35928" xml_f="36455" txt_i="19802" txt_f="20329">) consistently report that depressed patients are less adherent to their diabetes regimen and experience more physical complications of diabetes. Identifying youth who are at risk for poor medication adherence early in the course of disease would make it possible to provide support and, if needed, specific treatment. Although we were not able to determine whether the treatment of depressive symptoms changed adherence over time, our findings support the current guidelines for psychosocial screening in youth with diabetes (</offsets><xref rid="B29" ref-type="bibr"><offsets xml_i="36487" xml_f="36489" txt_i="20329" txt_f="20331">29</offsets></xref><offsets xml_i="36496" xml_f="36497" txt_i="20331" txt_f="20332">,</offsets><xref rid="B30" ref-type="bibr"><offsets xml_i="36529" xml_f="36531" txt_i="20332" txt_f="20334">30</offsets></xref><offsets xml_i="36538" xml_f="36718" txt_i="20334" txt_f="20514">). Clinicians may also need to evaluate adherence more carefully in patients with clinically significant depressive symptoms in order to identify and address barriers to adherence.</offsets></p><p><offsets xml_i="36725" xml_f="37337" txt_i="20515" txt_f="21127">With regard to the TODAY study primary outcome, we did not find an adherence threshold that predicted loss of glycemic control. Adherence to oral medication was related to higher insulin sensitivity, as expected for the pharmacological mechanisms of action of M+R. However, improved insulin sensitivity was not adequate to compensate for the ongoing decline in β-cell function. These results are consistent with results in adults from the UK Prospective Diabetes Study (UKPDS), in which a continuous decline in β-cell function in adults with type 2 diabetes was seen, irrespective of glucose-lowering treatment (</offsets><xref rid="B31" ref-type="bibr"><offsets xml_i="37369" xml_f="37371" txt_i="21127" txt_f="21129">31</offsets></xref><offsets xml_i="37378" xml_f="37493" txt_i="21129" txt_f="21244">). Furthermore, the durability of glycemic control in TODAY was not associated with lower adherence to medication (</offsets><xref rid="B32" ref-type="bibr"><offsets xml_i="37525" xml_f="37527" txt_i="21244" txt_f="21246">32</offsets></xref><offsets xml_i="37534" xml_f="38068" txt_i="21246" txt_f="21780">). Unlike adults with type 2 diabetes, loss of glycemic control in the TODAY trial occurred around the end of the first year in a significant portion of the cohort. During this first year, adherence for the majority of the cohort was ≥80%. This points to the progressive nature of type 2 diabetes seen in approximately half of TODAY youth as well as other factors, including the effects of pubertal hormones. Compared with adult-onset diabetes, youth-onset type 2 diabetes is associated with faster deterioration in glycemic control (</offsets><xref rid="B33" ref-type="bibr"><offsets xml_i="38100" xml_f="38102" txt_i="21780" txt_f="21782">33</offsets></xref><offsets xml_i="38109" xml_f="38141" txt_i="21782" txt_f="21814">) as well as insulin secretion (</offsets><xref rid="B34" ref-type="bibr"><offsets xml_i="38173" xml_f="38175" txt_i="21814" txt_f="21816">34</offsets></xref><offsets xml_i="38182" xml_f="38200" txt_i="21816" txt_f="21834">). Other studies (</offsets><xref rid="B35" ref-type="bibr"><offsets xml_i="38232" xml_f="38234" txt_i="21834" txt_f="21836">35</offsets></xref><offsets xml_i="38241" xml_f="38242" txt_i="21836" txt_f="21837">–</offsets><xref rid="B38" ref-type="bibr"><offsets xml_i="38274" xml_f="38276" txt_i="21837" txt_f="21839">38</offsets></xref><offsets xml_i="38283" xml_f="38461" txt_i="21839" txt_f="22017">) have reported that youths with type 2 diabetes are also at higher risk for comorbidities (e.g., microalbuminuria and dyslipidemia) earlier in the course of disease progression.</offsets></p><p><offsets xml_i="38468" xml_f="38640" txt_i="22018" txt_f="22190">The erosion of medication adherence seen in the TODAY trial is similar to the results of medication adherence deterioration over time in pediatric type 1 diabetes studies (</offsets><xref rid="B39" ref-type="bibr"><offsets xml_i="38672" xml_f="38674" txt_i="22190" txt_f="22192">39</offsets></xref><offsets xml_i="38681" xml_f="38682" txt_i="22192" txt_f="22193">,</offsets><xref rid="B40" ref-type="bibr"><offsets xml_i="38714" xml_f="38716" txt_i="22193" txt_f="22195">40</offsets></xref><offsets xml_i="38723" xml_f="38787" txt_i="22195" txt_f="22259">). Literature reviews of clinical trials and clinical practice (</offsets><xref rid="B41" ref-type="bibr"><offsets xml_i="38819" xml_f="38821" txt_i="22259" txt_f="22261">41</offsets></xref><offsets xml_i="38828" xml_f="38829" txt_i="22261" txt_f="22262">–</offsets><xref rid="B43" ref-type="bibr"><offsets xml_i="38861" xml_f="38863" txt_i="22262" txt_f="22264">43</offsets></xref><offsets xml_i="38870" xml_f="39094" txt_i="22264" txt_f="22488">) report that rates of adherence for adolescents with chronic illnesses vary, depending on the disease, the complexity of the treatment regimen, and the adherence measures used. However, there is a consensus across studies (</offsets><xref rid="B4" ref-type="bibr"><offsets xml_i="39125" xml_f="39126" txt_i="22488" txt_f="22489">4</offsets></xref><offsets xml_i="39133" xml_f="39134" txt_i="22489" txt_f="22490">,</offsets><xref rid="B44" ref-type="bibr"><offsets xml_i="39166" xml_f="39168" txt_i="22490" txt_f="22492">44</offsets></xref><offsets xml_i="39175" xml_f="39475" txt_i="22492" txt_f="22789">) that rates of adherence to medication are generally &lt;50%, especially for adolescents. As incentives were used to improve medication adherence in the TODAY trial, the observed erosion of adherence over time may also relate in part to an initial response to incentives with subsequent habituation.</offsets></p><p><offsets xml_i="39482" xml_f="39762" txt_i="22790" txt_f="23070">Limitations of the current report include the use of pill counts for measuring medication adherence and lack of adherence data when visits were missed. Pill counts as a measure of medication adherence often result in an overestimation of the actual number of pills taken. Rapoff (</offsets><xref rid="B4" ref-type="bibr"><offsets xml_i="39793" xml_f="39794" txt_i="23070" txt_f="23071">4</offsets></xref><offsets xml_i="39801" xml_f="40865" txt_i="23071" txt_f="24132">) has written that this is especially true in pediatric patients. Our criterion of ≥80% adherence for ≥8 weeks prior to randomization may also have selected for a more adherent cohort than is typical for youths with type 2 diabetes. Participants received coaching to improve medication adherence and could earn incentives for better adherence to medication, providing greater opportunity to improve adherence than would be present in general clinical care. Data were not kept on the rate of incentives attained by subjects in the TODAY trial. Although our cohort was relatively homogeneous with regard to demographic factors, the cohort is representative of the pediatric population with diagnosed type 2 diabetes. Although we assessed for clinically significant depressive symptoms, we did not track treatment for identified clinically significant depressive symptoms. The SEARCH and TODAY studies showed a similar sex (female predominance) and ethnic/racial distribution (majority Hispanic or African American), family income (majority making &lt;$50,000), BMI (</offsets><italic><offsets xml_i="40873" xml_f="40874" txt_i="24132" txt_f="24133">z</offsets></italic><offsets xml_i="40883" xml_f="40986" txt_i="24133" txt_f="24233">-score 2.1), family history of diabetes (&gt;70% in both), and C-peptide level (∼3.5 in both cohorts) (</offsets><xref rid="B45" ref-type="bibr"><offsets xml_i="41018" xml_f="41020" txt_i="24233" txt_f="24235">45</offsets></xref><offsets xml_i="41027" xml_f="41028" txt_i="24235" txt_f="24236">–</offsets><xref rid="B47" ref-type="bibr"><offsets xml_i="41060" xml_f="41062" txt_i="24236" txt_f="24238">47</offsets></xref><offsets xml_i="41069" xml_f="41071" txt_i="24238" txt_f="24240">).</offsets></p><p><offsets xml_i="41078" xml_f="42295" txt_i="24241" txt_f="25458">In conclusion, medication adherence showed similar declines over time in all three treatment groups and was not related to race-ethnicity or socioeconomic status in this cohort of primarily minority youth characterized by low household income and low parental education levels. The only participant characteristic that was related to low medication adherence was the presence of baseline clinically significant depressive symptoms. We found that no cutoff of medication adherence in the TODAY trial was related to time to treatment failure. Although medication adherence was associated with better insulin sensitivity, it could not compensate for the progressive decline in β-cell function. These results support the literature that type 2 diabetes in many youths runs a progressive course. For patients whose glycemic control is deteriorating while receiving therapy with M, the assessment of adherence and barriers to adherence must be addressed. However, in youths who are taking most of their medication, near 100% adherence is still unlikely to maintain glycemic control, and, thus, clinicians should consider intensification of therapy (pharmacologic and/or nonpharmacologic) early in the course of the disease.</offsets></p></sec></body><back><fn-group><fn id="fn1"><p>Clinical trial reg. no. NCT00081328, clinicaltrials.gov.</p></fn><fn id="fn2" fn-type="supplementary-material"><p>This article contains Supplementary Data online at <ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc15-2296/-/DC1">http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc15-2296/-/DC1</ext-link>.</p></fn><fn id="fn3"><label>*</label><p>A complete list of the TODAY Study Group can be found in the <ext-link ext-link-type="uri" xlink:href="http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dc15-2296/-/DC1">Supplementary Data</ext-link>.</p></fn></fn-group><ack><title>Article Information</title><p><bold>Acknowledgments.</bold> The TODAY Study Group thanks the following companies for donations in support of the study: Becton, Dickinson and Company; Bristol-Myers Squibb; Eli Lilly and Company; GlaxoSmithKline; LifeScan, Inc.; Pfizer; and Sanofi. The authors also thank the American Indian partners associated with the clinical center located at the University of Oklahoma Health Sciences Center, including members of the Absentee Shawnee Tribe, Cherokee Nation, Chickasaw Nation, Choctaw Nation of Oklahoma, and Oklahoma City Area Indian Health Service, for their participation and guidance.</p><p>The opinions expressed in this article are those of the authors and do not necessarily reflect the views of the respective Tribal and Indian Health Service Institution Review Boards or their members.</p><p><bold>Funding.</bold> This work was completed with funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institutes of Health Office of the Director through grants U01-DK-61212, U01-DK-61230, U01-DK-61239, U01-DK-61242, and U01-DK-61254.</p><p>The NIDDK project office was involved in all aspects of the study, including design and conduct; collection, management, analysis, and interpretation of the data; review and approval of the manuscript; and decision to submit the manuscript for publication.</p><p>The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p><p><bold>Duality of Interest.</bold> L.L.K. is a consultant to Takeda Phamaceuticals. No other potential conflicts of interest relevant to this article were reported.</p><p><bold>Author Contributions.</bold> L.L.K., B.J.A., S.V.M., and K.H. researched data, contributed to the discussion, wrote the manuscript, and reviewed and edited the manuscript. R.I. researched the data and reviewed and edited the manuscript. T.L.C., A.W., and K.J.N. researched the data, contributed to the discussion, and reviewed and edited the manuscript. L.A.H. researched the data and contributed to the discussion. K.H. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p><p><bold>Prior Presentation.</bold> Some of the data presented were reported in a presentation entitled “Study Medication Adherence and Outcomes in the TODAY Cohort of Youth With Type 2 Diabetes” by S.V.M. to the International Society for Pediatric and Adolescent Diabetes, Toronto, Ontario, Canada, 3 September 2014.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tamborlane</surname><given-names>WV</given-names></name>, <name name-style="western"><surname>Klingensmith</surname><given-names>G</given-names></name></person-group>. <article-title>Crisis in care: limited treatment options for type 2 diabetes in adolescents and youth</article-title>. <source>Diabetes Care</source>
<year>2013</year>;<volume>36</volume>:<fpage>1777</fpage>–<lpage>1778</lpage><pub-id pub-id-type="pmid">23704679</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeitler</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Hirst</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Pyle</surname><given-names>L</given-names></name>, <etal></etal>.; <collab>TODAY Study Group</collab></person-group>. <article-title>A clinical trial to maintain glycemic control in youth with type 2 diabetes</article-title>. <source>N Engl J Med</source>
<year>2012</year>;<volume>366</volume>:<fpage>2247</fpage>–<lpage>2256</lpage><pub-id pub-id-type="pmid">22540912</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walker</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Molitch</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kramer</surname><given-names>MK</given-names></name>, <etal></etal>.; <collab>DPP Research Group</collab></person-group>. <article-title>Adherence to preventive medications: predictors and outcomes in the Diabetes Prevention Program</article-title>. <source>Diabetes Care</source>
<year>2006</year>;<volume>29</volume>:<fpage>1997</fpage>–<lpage>2002</lpage><pub-id pub-id-type="pmid">16936143</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Rapoff</surname><given-names>MA</given-names></name></person-group>
<source>Adherence to Pediatric Medical Regimens</source>. <publisher-loc>New York, NY</publisher-loc>, <publisher-name>Kluwer Academic/Plenum Publishers</publisher-name>, <year>1999</year></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Auslander</surname><given-names>WF</given-names></name>, <name name-style="western"><surname>Thompson</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Dreitzer</surname><given-names>D</given-names></name>, <name name-style="western"><surname>White</surname><given-names>NH</given-names></name>, <name name-style="western"><surname>Santiago</surname><given-names>JV</given-names></name></person-group>. <article-title>Disparity in glycemic control and adherence between African-American and Caucasian youths with diabetes. Family and community contexts</article-title>. <source>Diabetes Care</source>
<year>1997</year>;<volume>20</volume>:<fpage>1569</fpage>–<lpage>1575</lpage><pub-id pub-id-type="pmid">9314637</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miller</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Beck</surname><given-names>RW</given-names></name>, <name name-style="western"><surname>Bergenstal</surname><given-names>RM</given-names></name>, <etal></etal>.; <collab>T1D Exchange Clinic Network</collab></person-group>. <article-title>Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants</article-title>. <source>Diabetes Care</source>
<year>2013</year>;<volume>36</volume>:<fpage>2009</fpage>–<lpage>2014</lpage><pub-id pub-id-type="pmid">23378621</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gallegos-Macias</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Macias</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Kaufman</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Skipper</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Kalishman</surname><given-names>N</given-names></name></person-group>. <article-title>Relationship between glycemic control, ethnicity and socioeconomic status in Hispanic and white non-Hispanic youths with type 1 diabetes mellitus</article-title>. <source>Pediatr Diabetes</source>
<year>2003</year>;<volume>4</volume>:<fpage>19</fpage>–<lpage>23</lpage><pub-id pub-id-type="pmid">14655519</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Lustman</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Griffith</surname><given-names>LS</given-names></name>, <name name-style="western"><surname>Clouse</surname><given-names>RE</given-names></name></person-group>
<article-title>Recognizing and managing depression in patients with diabetes</article-title>. In <source>Practical Psychology for Diabetes Clinicians</source>. <person-group person-group-type="editor"><name name-style="western"><surname>Anderson</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Rubin</surname><given-names>RR</given-names></name></person-group>, Eds. <publisher-loc>Alexandria, VA</publisher-loc>, <publisher-name>American Diabetes Association</publisher-name>, <year>2003</year>, p. <fpage>143</fpage>–<lpage>152</lpage></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Katon</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Felz-Cornelis</surname><given-names>C</given-names></name></person-group>
<article-title>Treatment of depression in patients with diabetes: efficacy, effectiveness and maintenance trials, and new service models</article-title>. In <source>Depression and Diabetes</source>. <person-group person-group-type="editor"><name name-style="western"><surname>Katon</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Maj</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sartorius</surname><given-names>N</given-names></name></person-group>, Eds. <publisher-loc>Hoboken, NY</publisher-loc>, <publisher-name>Wiley-Blackwell</publisher-name>, <year>2010</year>, p. <fpage>81</fpage>–<lpage>107</lpage></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nguyen</surname><given-names>TT</given-names></name>, <name name-style="western"><surname>Jayadeva</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Cizza</surname><given-names>G</given-names></name>, <etal></etal></person-group>. <article-title>Challenging recruitment of youth with type 2 diabetes into clinical trials</article-title>. <source>J Adolesc Health</source>
<year>2014</year>;<volume>54</volume>:<fpage>247</fpage>–<lpage>254</lpage><pub-id pub-id-type="pmid">24161585</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeitler</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Epstein</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Grey</surname><given-names>M</given-names></name>, <etal></etal>.; <collab>TODAY Study Group</collab></person-group>. <article-title>Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes</article-title>. <source>Pediatr Diabetes</source>
<year>2007</year>;<volume>8</volume>:<fpage>74</fpage>–<lpage>87</lpage><pub-id pub-id-type="pmid">17448130</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilfley</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Tibbs</surname><given-names>TL</given-names></name>, <name name-style="western"><surname>Van Buren</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Reach</surname><given-names>KP</given-names></name>, <name name-style="western"><surname>Walker</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Epstein</surname><given-names>LH</given-names></name></person-group>. <article-title>Lifestyle interventions in the treatment of childhood overweight: a meta-analytic review of randomized controlled trials</article-title>. <source>Health Psychol</source>
<year>2007</year>;<volume>26</volume>:<fpage>521</fpage>–<lpage>532</lpage><pub-id pub-id-type="pmid">17845100</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalarchian</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Levine</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Arslanian</surname><given-names>SA</given-names></name>, <etal></etal></person-group>. <article-title>Family-based treatment of severe pediatric obesity: randomized, controlled trial</article-title>. <source>Pediatrics</source>
<year>2009</year>;<volume>124</volume>:<fpage>1060</fpage>–<lpage>1068</lpage><pub-id pub-id-type="pmid">19786444</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilfley</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Stein</surname><given-names>RI</given-names></name>, <name name-style="western"><surname>Saelens</surname><given-names>BE</given-names></name>, <etal></etal></person-group>. <article-title>Efficacy of maintenance treatment approaches for childhood overweight: a randomized controlled trial</article-title>. <source>JAMA</source>
<year>2007</year>;<volume>298</volume>:<fpage>1661</fpage>–<lpage>1673</lpage><pub-id pub-id-type="pmid">17925518</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varni</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Limbers</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Burwinkle</surname><given-names>TM</given-names></name></person-group>. <article-title>Impaired health-related quality of life in children and adolescents with chronic conditions: a comparative analysis of 10 disease clusters and 33 disease categories/severities utilizing the PedsQL 4.0 Generic Core Scales</article-title>. <source>Health Qual Life Outcomes</source>
<year>2007</year>;<volume>5</volume>:<fpage>43</fpage><pub-id pub-id-type="pmid">17634123</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Kovacs</surname><given-names>M</given-names></name></person-group>
<source>The Children’s Depression Inventory Manual</source>. <publisher-loc>New York, NY</publisher-loc>, <publisher-name>Multi-Health Systems</publisher-name>, <year>1992</year></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Beck</surname><given-names>AT</given-names></name>, <name name-style="western"><surname>Steer</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>GK</given-names></name></person-group>
<source>Manual for the Beck Depression Inventory-II</source>. <publisher-loc>San Antonio, TX</publisher-loc>, <publisher-name>Psychological Corporation</publisher-name>, <year>1996</year></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>George</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Bacha</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Tfayli</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Andreatta</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Arslanian</surname><given-names>S</given-names></name></person-group>. <article-title>Surrogate estimates of insulin sensitivity in obese youth along the spectrum of glucose tolerance from normal to prediabetes to diabetes</article-title>. <source>J Clin Endocrinol Metab</source>
<year>2011</year>;<volume>96</volume>:<fpage>2136</fpage>–<lpage>2145</lpage><pub-id pub-id-type="pmid">21508130</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brar</surname><given-names>PC</given-names></name>, <name name-style="western"><surname>Koren</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Gallagher</surname><given-names>PR</given-names></name>, <name name-style="western"><surname>Pendurthi</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Katz</surname><given-names>LEL</given-names></name></person-group>. <article-title>Comparison of oral and intravenous glucose tolerance test derived sensitivity and secretory indices in obese adolescents</article-title>. <source>Clin Pediatr (Phila)</source>
<year>2013</year>;<volume>52</volume>:<fpage>247</fpage>–<lpage>253</lpage><pub-id pub-id-type="pmid">23418053</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Utzschneider</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Prigeon</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Faulenbach</surname><given-names>MV</given-names></name>, <etal></etal></person-group>. <article-title>Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels</article-title>. <source>Diabetes Care</source>
<year>2009</year>;<volume>32</volume>:<fpage>335</fpage>–<lpage>341</lpage><pub-id pub-id-type="pmid">18957530</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Edelstein</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Abramson</surname><given-names>NW</given-names></name>, <etal></etal>.; <collab>TODAY Study Group</collab></person-group>. <article-title>Depressive symptoms and quality of life in adolescents with type 2 diabetes: baseline data from the TODAY study</article-title>. <source>Diabetes Care</source>
<year>2011</year>;<volume>34</volume>:<fpage>2205</fpage>–<lpage>2207</lpage><pub-id pub-id-type="pmid">21836107</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lawrence</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Standiford</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Loots</surname><given-names>B</given-names></name>, <etal></etal>.; <collab>SEARCH for Diabetes in Youth Study</collab></person-group>. <article-title>Prevalence and correlates of depressed mood among youth with diabetes: the SEARCH for Diabetes in Youth study</article-title>. <source>Pediatrics</source>
<year>2006</year>;<volume>117</volume>:<fpage>1348</fpage>–<lpage>1358</lpage><pub-id pub-id-type="pmid">16585333</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>De Groot</surname><given-names>M</given-names></name></person-group>
<article-title>Depression and diabetes</article-title>. In <source>Psychosocial Care for People with Diabetes</source>. <person-group person-group-type="editor"><name name-style="western"><surname>Young-Hyman</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Peyrot</surname><given-names>M</given-names></name></person-group>, Eds. <publisher-loc>Alexandria, VA</publisher-loc>, <publisher-name>American Diabetes Association</publisher-name>, <year>2012</year>, p. <fpage>1</fpage>–<lpage>16</lpage></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Groot</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Anderson</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Freedland</surname><given-names>KE</given-names></name>, <name name-style="western"><surname>Clouse</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Lustman</surname><given-names>PJ</given-names></name></person-group>. <article-title>Association of depression and diabetes complications: a meta-analysis</article-title>. <source>Psychosom Med</source><year>2001</year>;<volume>63</volume>:<fpage>619</fpage>–<lpage>630</lpage><pub-id pub-id-type="pmid">11485116</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gross</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Olfson</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Gameroff</surname><given-names>MJ</given-names></name>, <etal></etal></person-group>. <article-title>Depression and glycemic control in Hispanic primary care patients with diabetes</article-title>. <source>J Gen Intern Med</source>
<year>2005</year>;<volume>20</volume>:<fpage>460</fpage>–<lpage>466</lpage><pub-id pub-id-type="pmid">15963173</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lustman</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Anderson</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Freedland</surname><given-names>KE</given-names></name>, <name name-style="western"><surname>de Groot</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Carney</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Clouse</surname><given-names>RE</given-names></name></person-group>. <article-title>Depression and poor glycemic control: a meta-analytic review of the literature</article-title>. <source>Diabetes Care</source>
<year>2000</year>;<volume>23</volume>:<fpage>934</fpage>–<lpage>942</lpage><pub-id pub-id-type="pmid">10895843</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lustman</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Griffith</surname><given-names>LS</given-names></name>, <name name-style="western"><surname>Freedland</surname><given-names>KE</given-names></name>, <name name-style="western"><surname>Clouse</surname><given-names>RE</given-names></name></person-group>. <article-title>The course of major depression in diabetes</article-title>. <source>Gen Hosp Psychiatry</source>
<year>1997</year>;<volume>19</volume>:<fpage>138</fpage>–<lpage>143</lpage><pub-id pub-id-type="pmid">9097068</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagner</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Tennen</surname><given-names>H</given-names></name></person-group>. <article-title>History of major depressive disorder and diabetes outcomes in diet- and tablet-treated post-menopausal women: a case control study</article-title>. <source>Diabet Med</source>
<year>2007</year>;<volume>24</volume>:<fpage>211</fpage>–<lpage>216</lpage><pub-id pub-id-type="pmid">17257286</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>American Diabetes Association</collab></person-group>. <article-title>(11) Children and adolescents</article-title>. <source>Diabetes Care</source>
<year>2015</year>;<volume>38</volume>(<issue>Suppl.</issue>):<fpage>S70</fpage>–<lpage>S76</lpage><pub-id pub-id-type="pmid">25537712</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delamater</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>de Wit</surname><given-names>M</given-names></name>, <name name-style="western"><surname>McDarby</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Malik</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Acerini</surname><given-names>CL</given-names></name>.; <collab>International Society for Pediatric and Adolescent Diabetes</collab></person-group>. <article-title>ISPAD Clinical Practice Consensus Guidelines 2014. Psychological care of children and adolescents with type 1 diabetes</article-title>. <source>Pediatr Diabetes</source>
<year>2014</year>;<volume>15</volume>(<issue>Suppl. 20</issue>):<fpage>232</fpage>–<lpage>244</lpage><pub-id pub-id-type="pmid">25182317</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>U.K. Prospective Diabetes Study Group</collab></person-group>. <article-title>U.K. prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease</article-title>. <source>Diabetes</source>
<year>1995</year>;<volume>44</volume>:<fpage>1249</fpage>–<lpage>1258</lpage><pub-id pub-id-type="pmid">7589820</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zeitler</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Hirst</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Copeland</surname><given-names>KC</given-names></name>, <etal></etal>.; <collab>TODAY Study Group</collab></person-group>. <article-title>HbA1C after a short period of monotherapy with metformin identifies durable glycemic control among adolescents with type 2 diabetes</article-title>. <source>Diabetes Care</source>
<year>2015</year>;<volume>38</volume>:<fpage>2285</fpage>–<lpage>2292</lpage><pub-id pub-id-type="pmid">26537182</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levitt Katz</surname><given-names>LE</given-names></name>, <name name-style="western"><surname>Magge</surname><given-names>SN</given-names></name>, <name name-style="western"><surname>Hernandez</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Murphy</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>McKnight</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Lipman</surname><given-names>T</given-names></name></person-group>. <article-title>Glycemic control in youth with type 2 diabetes declines as early as two years after diagnosis</article-title>. <source>J Pediatr</source>
<year>2011</year>;<volume>158</volume>:<fpage>106</fpage>–<lpage>111</lpage><pub-id pub-id-type="pmid">20797726</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>TODAY Study Group</collab></person-group>. <article-title>Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY</article-title>. <source>Diabetes Care</source>
<year>2013</year>;<volume>36</volume>:<fpage>1749</fpage>–<lpage>1757</lpage><pub-id pub-id-type="pmid">23704674</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dart</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Martens</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Rigatto</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Brownell</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Dean</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Sellers</surname><given-names>EA</given-names></name></person-group>. <article-title>Earlier onset of complications in youth with type 2 diabetes</article-title>. <source>Diabetes Care</source>
<year>2014</year>;<volume>37</volume>:<fpage>436</fpage>–<lpage>443</lpage><pub-id pub-id-type="pmid">24130346</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Constantino</surname><given-names>MI</given-names></name>, <name name-style="western"><surname>Molyneaux</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Limacher-Gisler</surname><given-names>F</given-names></name>, <etal></etal></person-group>. <article-title>Long-term complications and mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes</article-title>. <source>Diabetes Care</source>
<year>2013</year>;<volume>36</volume>:<fpage>3863</fpage>–<lpage>3869</lpage><pub-id pub-id-type="pmid">23846814</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>TODAY Study Group</collab></person-group>. <article-title>Rapid rise in hypertension and nephropathy in youth with type 2 diabetes: the TODAY clinical trial</article-title>. <source>Diabetes Care</source>
<year>2013</year>;<volume>36</volume>:<fpage>1735</fpage>–<lpage>1741</lpage><pub-id pub-id-type="pmid">23704672</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pavkov</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Bennett</surname><given-names>PH</given-names></name>, <name name-style="western"><surname>Knowler</surname><given-names>WC</given-names></name>, <name name-style="western"><surname>Krakoff</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Sievers</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Nelson</surname><given-names>RG</given-names></name></person-group>. <article-title>Effect of youth-onset type 2 diabetes mellitus on incidence of end-stage renal disease and mortality in young and middle-aged Pima Indians</article-title>. <source>JAMA</source>
<year>2006</year>;<volume>296</volume>:<fpage>421</fpage>–<lpage>426</lpage><pub-id pub-id-type="pmid">16868300</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacobson</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Hauser</surname><given-names>ST</given-names></name>, <name name-style="western"><surname>Lavori</surname><given-names>P</given-names></name>, <etal></etal></person-group>. <article-title>Adherence among children and adolescents with insulin-dependent diabetes mellitus over a four-year longitudinal follow-up: I. The influence of patient coping and adjustment</article-title>. <source>J Pediatr Psychol</source>
<year>1990</year>;<volume>15</volume>:<fpage>511</fpage>–<lpage>526</lpage><pub-id pub-id-type="pmid">2258798</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kovacs</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Goldston</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Obrosky</surname><given-names>DS</given-names></name>, <name name-style="western"><surname>Iyengar</surname><given-names>S</given-names></name></person-group>. <article-title>Prevalence and predictors of pervasive noncompliance with medical treatment among youths with insulin-dependent diabetes mellitus</article-title>. <source>J Am Acad Child Adolesc Psychiatry</source>
<year>1992</year>;<volume>31</volume>:<fpage>1112</fpage>–<lpage>1119</lpage><pub-id pub-id-type="pmid">1429414</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bond</surname><given-names>WS</given-names></name>, <name name-style="western"><surname>Hussar</surname><given-names>DA</given-names></name></person-group>. <article-title>Detection methods and strategies for improving medication compliance</article-title>. <source>Am J Hosp Pharm</source>
<year>1991</year>;<volume>48</volume>:<fpage>1978</fpage>–<lpage>1988</lpage><pub-id pub-id-type="pmid">1928147</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quittner</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Modi</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Lemanek</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Ievers-Landis</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Rapoff</surname><given-names>MA</given-names></name></person-group>. <article-title>Evidence-based assessment of adherence to medical treatments in pediatric psychology</article-title>. <source>J Pediatr Psychol</source>
<year>2008</year>;<volume>33</volume>:<fpage>916</fpage>–<lpage>936</lpage><pub-id pub-id-type="pmid">17846042</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanghøj</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Boisen</surname><given-names>KA</given-names></name></person-group>. <article-title>Self-reported barriers to medication adherence among chronically ill adolescents: a systematic review</article-title>. <source>J Adolesc Health</source>
<year>2014</year>;<volume>54</volume>:<fpage>121</fpage>–<lpage>138</lpage><pub-id pub-id-type="pmid">24182940</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunbar-Jacob</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Mortimer-Stephens</surname><given-names>MK</given-names></name></person-group>. <article-title>Treatment adherence in chronic disease</article-title>. <source>J Clin Epidemiol</source>
<year>2001</year>;<volume>54</volume>(<issue>Suppl. 1</issue>):<fpage>S57</fpage>–<lpage>S60</lpage><pub-id pub-id-type="pmid">11750211</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mayer-Davis</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Beyer</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Bell</surname><given-names>RA</given-names></name>, <etal></etal>.; <collab>SEARCH for Diabetes in Youth Study Group</collab></person-group>. <article-title>Diabetes in African American youth: prevalence, incidence, and clinical characteristics: the SEARCH for Diabetes in Youth Study</article-title>. <source>Diabetes Care</source>
<year>2009</year>;<volume>32</volume>(<issue>Suppl. 2</issue>):<fpage>S112</fpage>–<lpage>S122</lpage><pub-id pub-id-type="pmid">19246576</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bell</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Mayer-Davis</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Beyer</surname><given-names>JW</given-names></name>, <etal></etal>.; <collab>SEARCH for Diabetes in Youth Study Group</collab></person-group>
<article-title>Diabetes in non-Hispanic white youth: prevalence, incidence, and clinical characteristics: the SEARCH for Diabetes in Youth Study</article-title>. <source>Diabetes Care</source>
<year>2009</year>;<volume>32</volume>(<issue>Suppl. 2</issue>):<fpage>S102</fpage>–<lpage>S111</lpage><pub-id pub-id-type="pmid">19246575</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dabelea</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Mayer-Davis</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Saydah</surname><given-names>S</given-names></name>, <etal></etal>.; <collab>SEARCH for Diabetes in Youth Study</collab></person-group>. <article-title>Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009</article-title>. <source>JAMA</source>
<year>2014</year>;<volume>311</volume>:<fpage>1778</fpage>–<lpage>1786</lpage><pub-id pub-id-type="pmid">24794371</pub-id></mixed-citation></ref></ref-list></back></article>